First National Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

First National Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,489	Closed	-$302K	–	376
2023 Q2	$302K	Sell	3,489 -6,062	-63%	-$570K	0.01%	318
2023 Q1	$929K	Sell	9,551 -2,387	-20%	-$247K	0.05%	205
2022 Q4	$1.24M	Sell	11,938 -9,721	-45%	-$913K	0.07%	173
2022 Q3	$1.84M	Sell	21,659 -59,869	-73%	-$5.33M	0.11%	152
2022 Q2	$6.76M	Sell	81,528 -2,331	-3%	-$186K	0.38%	75
2022 Q1	$6.47M	Buy	83,859 +6,874	+9%	+$575K	0.34%	89
2021 Q4	$6.8M	Buy	76,985 +5,129	+7%	+$423K	0.36%	89
2021 Q3	$5.55M	Buy	71,856 +3,099	+5%	+$245K	0.33%	88
2021 Q2	$5.74M	Buy	68,757 +13,455	+24%	+$1.07M	0.35%	90
2021 Q1	$4.17M	Buy	+55,302	New	+$4.52M	0.27%	99

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

First National Trust's BMRN Position: Q3 2023 in Review

First National Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 3,489 shares — an estimated $302K sold.

First National Trust first reported a position in BMRN in Q1 2021 and held it in 10 quarters. The position peaked at $6.8M in Q4 2021. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

First National Trust reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
First National Trust sold 3,489 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $302K.
First National Trust first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 10 quarters.
First National Trust's BioMarin Pharmaceuticals position peaked at $6.8M in Q4 2021.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on First National Trust's 13F filing for Q3 2023, filed 6 Nov 2023.